Skip to main content
Novartis
language-selector-globe
Choose Location
  • Americas
  • Asia Pacific
  • Europe
  • International
  • Middle East & Africa
Argentina | Español
Brazil | Português
Canada | English
Canada | Français
Central America | Español
Colombia | Español
Mexico | Español
United States | English
Australia | English
Bangladesh | English
Hong Kong S.A.R. | 繁體中文
India | English
Indonesia | English
Japan | 日本語
Korea | 한국어
Mainland China | 中文
Malaysia | English
Pakistan | English
Philippines | English
Singapore | English
Taiwan | 繁體中文
Thailand | ภาษาไทย
Austria | Deutsch
Belgium | Français
Belgium | Nederlands
Bulgaria | Български
Czech Republic | Česky
Czech Republic | English
Denmark | Dansk
Estonia | Eesti
Finland | Suomalainen
France | Français
Germany | Deutsch
Greece | Ελληνικά
Hungary | Magyar
Ireland | English
Italy | Italiano
Latvia | Latvian
Lithuania | Lithuanian
Netherlands | Nederlands
Norway | Norsk
Poland | Polski
Portugal | Português
Romania | Română
Russia | Русский
Serbia | Srpski
Slovakia | Slovensky
Slovenia | Slovenščina
Slovenia | English
Spain | Español
Sweden | Svenska
Switzerland | Deutsch
Switzerland | Français
Türkiye | Türkçe
United Kingdom | English
Global | English
Novartis Foundation | English
Egypt | English
Israel | עברית
Saudi Arabia | العربية
South Africa | English
language-selector-globe
Choose Location
Americas Asia Pacific Europe International Middle East & Africa
Argentina | Español
Australia | English
Austria | Deutsch
Bangladesh | English
Belgium | Français
Belgium | Nederlands
Brazil | Português
Bulgaria | Български
Canada | English
Canada | Français
Central America | Español
Colombia | Español
Czech Republic | Česky
Czech Republic | English
Denmark | Dansk
Egypt | English
Estonia | Eesti
Finland | Suomalainen
France | Français
Germany | Deutsch
Greece | Ελληνικά
Hong Kong S.A.R. | 繁體中文
Hungary | Magyar
India | English
Indonesia | English
Ireland | English
Israel | עברית
Italy | Italiano
Japan | 日本語
Korea | 한국어
Latvia | Latvian
Lithuania | Lithuanian
Mainland China | 中文
Malaysia | English
Mexico | Español
Netherlands | Nederlands
Norway | Norsk
Global | English
Novartis Foundation | English
Pakistan | English
Philippines | English
Poland | Polski
Portugal | Português
Romania | Română
Russia | Русский
Saudi Arabia | العربية
Serbia | Srpski
Singapore | English
Slovakia | Slovensky
Slovenia | Slovenščina
Slovenia | English
South Africa | English
Spain | Español
Sweden | Svenska
Switzerland | Deutsch
Switzerland | Français
Taiwan | 繁體中文
Thailand | ภาษาไทย
Türkiye | Türkçe
United Kingdom | English
United States | English
    • About 
      • Novartis in Philippines 
      • Strategy 
      • Diversity and Inclusion 
      • People and Culture 
      • Products 
      • Country Leadership Team 
      • Contact 
      Novartis Philippines About
      About
    • Patients and Caregivers 
      • Novartis Commitment to Patients and Caregivers 
      • Diseases 
      • Patient resources 
      • Products 
      • Adverse Event Reporting 
      Patients and Caregivers
      Patients and Caregivers
    • Healthcare Professionals 
      • Healthcare professional country resource 
      • Products 
      • Novartis Pipeline 
      • Adverse Event Reporting 
      • Novartis Clinical Trials 
      Scientist in a lab
      Healthcare Professionals
    • ESG 
      • Financial Transparency for Philippines 
      • Ethical Behavior 
        • Code of Ethics 
        • SpeakUp 
      • Ethics, Risk and Compliance 
      • Access 
      • Environmental Sustainability 
      • Global Health 
      ESG
      ESG
    • News 
      • News Archive 
      • Stories 
      • Contacts 
      Business people, talking in a meeting room
      News
    • Careers 
      • Career Search 
      • Meet the teams 
      • Early Talent 
      • How We Work 
      • Diversity and Inclusion 
      • Career Programs 
      • Awards and Recognition 
      Careers
      Careers
    • Coronavirus 
      Coronavirus under the microscope
      Coronavirus
    Home Novartis Philippines
    Home
Header
Person making exercises under a tree

Environment, Society and Governance

As a global company, Novartis has a great responsibility and an even greater opportunity to lead the world in creating a positive social change, embracing societal impact as a core business objective.
Photo of people walking

Ethics, Risk and Compliance

We recognize society’s expectations of our industry and of Novartis, and that we must go beyond just doing what is legal in order to meet legitimate expectations of society.

Access to medicines

Access to medicines

We believe access to medicines is where we can have the greatest impact. For all our new medicines, we systematically integrate access strategies to reach underserved patients no matter where they live.

Trees in a forest

Environmental Sustainability

We understand the link between the health of our planet and the health of our patients. Our ambition is to be a catalyst for positive change and a leader in environmental sustainability.

Global Health

Global Health

We apply our expertise and full organizational capability to address major, unresolved global health challenges.

Diversity & Inclusion

Diversity & Inclusion

We embrace and champion diversity and inclusion which fuels innovation, drives engagement, and attracts talent.

Business people meeting in a room

Materiality Assessment and Reporting

Our ESG priorities are defined by our materiality assessment, it helps us understand what matters to our stakeholders and how they perceive our impact

Novartis Philippines

Navigate Novartis
  • Patients & Caregivers
  • Healthcare Professionals
  • ESG
  • News
  • Careers
Media Center
  • News Archive
  • Stories
Our Portfolio
  • Novartis Clinical Pipeline
  • Novartis Product Portfolio
NPC Seal of Registration
Footer Bottom
© 2025 Novartis AG
  • Privacy Policy
  • Terms of Use
  • Cookie Settings
  • Site Map
  • Web Accessibility
Novartis Site Directory
This site is intended for an audience in the Philippines